ALX Oncology Inc. (ALXO)
0.50
-0.03 (-6.21%)
At close: Apr 04, 2025, 3:41 PM
-6.21% (1D)
| Bid | 0.37 |
| Market Cap | 26.82M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -2.58 |
| PE Ratio (ttm) | -0.19 |
| Forward PE | -0.73 |
| Analyst | Buy |
| Ask | 0.63 |
| Volume | 553,593 |
| Avg. Volume (20D) | 1,034,327 |
| Open | 0.52 |
| Previous Close | 0.53 |
| Day's Range | 0.48 - 0.54 |
| 52-Week Range | 0.48 - 17.82 |
| Beta | 1.20 |
About ALXO
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell c...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 17, 2020
Employees 80
Stock Exchange NASDAQ
Ticker Symbol ALXO
Website https://www.alxoncology.com
Analyst Forecast
According to 6 analyst ratings, the average rating for ALXO stock is "Buy." The 12-month stock price forecast is $3, which is an increase of 497.13% from the latest price.
Stock Forecasts4 weeks ago
-19.08%
ALX Oncology Holdings shares are trading lower. Th...
Unlock content with
Pro Subscription
4 weeks ago
+25.96%
ALX Oncology Holdings shares are trading higher after Piper Sandler and Jefferies upgraded their respective price targets on the stock.
